Stage-Specific Value of Carbohydrate Antigen 19-9 and Carcinoembryonic Antigen Serum Levels on Survival and Recurrence in Pancreatic Cancer: A Single Center Study and Meta-Analysis

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2020 Oct 17

PMID 33066393

Citations 13

Authors

Labrinus van Manen

Jesse V Groen

Hein Putter

Martin Pichler

Alexander L Vahrmeijer

Bert A Bonsing

J Sven D Mieog

Affiliations

Soon will be listed here.

Abstract

This study aimed to determine the stage-specific prognostic value of carbohydrate antigen 19-9 (CA19-9) and carcinoembryonic antigen (CEA) serum levels at diagnosis on overall survival (OS) and time to local recurrence or distant metastases in patients with pancreatic ductal adenocarcinoma (PDAC). Consecutive PDAC patients, discussed at multidisciplinary team meetings from 2013 through 2017, were reviewed. Prognostic factors were stage-specific (resection vs. advanced PDAC) evaluated in Cox proportional hazard models. Additionally, a systematic literature search and meta-analysis was performed, as current literature is lacking a complete overview of used cut-off values and the added value of CEA as prognostic marker. In the retrospective cohort, elevated CA19-9 (>305 kU/L) level was independently associated with poor OS (Hazard ratio (HR): 1.72(1.31-2.26)) and early recurrence (HR: 1.74(1.06-2.86)), whereas CEA was not significantly associated. The meta-analysis showed that both elevated CA19-9 and CEA serum levels were predictors for poor OS (pooled HR: 1.29(1.17-1.42) and HR: 1.51(1.33-1.73), respectively). In the resected cohort, elevated CA19-9 level was significantly associated with early recurrence (pooled HR: 2.41(1.77-3.29)), whereas CEA was not. Elevated CA19-9 serum level appear to be an independent prognostic factor for poor OS and early recurrence in PDAC patients, whereas the prognostic value of CEA is disputable.

Citing Articles

Combining prognostic value of serum carbohydrate antigen 19-9 and tumor size reduction ratio in pancreatic ductal adenocarcinoma.

Xia D, Zhou Y, Yang S, Li F, Tian L, Li Y World J Gastrointest Oncol. 2024; 16(3):798-809.

PMID: 38577439 PMC: 10989379. DOI: 10.4251/wjgo.v16.i3.798.

Globo H ceramide is an independent prognostic marker for gallbladder cancer.

Hung T, Yeh C, Hung J, Wu C, Lee C, Yu J Am J Cancer Res. 2023; 13(10):4811-4821.

PMID: 37970342 PMC: 10636676.

NANOBODY Molecule, a Giga Medical Tool in Nanodimensions.

Kunz S, Durandy M, Seguin L, Feral C Int J Mol Sci. 2023; 24(17).

PMID: 37686035 PMC: 10487883. DOI: 10.3390/ijms241713229.

Factors predicting recurrence after left‑sided pancreatectomy for pancreatic ductal adenocarcinoma.

Xia T, Xu P, Mou Y, Zhang X, Song S, Zhou Y World J Surg Oncol. 2023; 21(1):191.

PMID: 37349737 PMC: 10286495. DOI: 10.1186/s12957-023-03080-z.

Near-Infrared Fluorescence Imaging of Pancreatic Cancer Using a Fluorescently Labelled Anti-CEA Nanobody Probe: A Preclinical Study.

van Manen L, de Muynck L, Baart V, Bhairosingh S, Debie P, Vahrmeijer A Biomolecules. 2023; 13(4).

PMID: 37189366 PMC: 10135789. DOI: 10.3390/biom13040618.

References

Dong Q, Yang X, Zhang Y, Jing W, Zheng L, Liu Y . Elevated serum CA19-9 level is a promising predictor for poor prognosis in patients with resectable pancreatic ductal adenocarcinoma: a pilot study. World J Surg Oncol. 2014; 12:171. PMC: 4064278. DOI: 10.1186/1477-7819-12-171. View

Campbell F, Smith R, Whelan P, Sutton R, Raraty M, Neoptolemos J . Classification of R1 resections for pancreatic cancer: the prognostic relevance of tumour involvement within 1 mm of a resection margin. Histopathology. 2009; 55(3):277-83. DOI: 10.1111/j.1365-2559.2009.03376.x. View

Liberati A, Altman D, Tetzlaff J, Mulrow C, Gotzsche P, Ioannidis J . The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009; 339:b2700. PMC: 2714672. DOI: 10.1136/bmj.b2700. View

Siegel R, Miller K, Jemal A . Cancer statistics, 2018. CA Cancer J Clin. 2018; 68(1):7-30. DOI: 10.3322/caac.21442. View

Tingle S, Severs G, Goodfellow M, Moir J, White S . NARCA: A novel prognostic scoring system using neutrophil-albumin ratio and Ca19-9 to predict overall survival in palliative pancreatic cancer. J Surg Oncol. 2018; 118(4):680-686. DOI: 10.1002/jso.25209. View

Ferrone C, Finkelstein D, Thayer S, Muzikansky A, Fernandez-delCastillo C, Warshaw A . Perioperative CA19-9 levels can predict stage and survival in patients with resectable pancreatic adenocarcinoma. J Clin Oncol. 2006; 24(18):2897-902. PMC: 3817569. DOI: 10.1200/JCO.2005.05.3934. View

Luo G, Liu C, Guo M, Cheng H, Lu Y, Jin K . Potential Biomarkers in Lewis Negative Patients With Pancreatic Cancer. Ann Surg. 2017; 265(4):800-805. DOI: 10.1097/SLA.0000000000001741. View

Imaoka H, Shimizu Y, Senda Y, Natsume S, Mizuno N, Hara K . Post-adjuvant chemotherapy CA19-9 levels predict prognosis in patients with pancreatic ductal adenocarcinoma: A retrospective cohort study. Pancreatology. 2016; 16(4):658-64. DOI: 10.1016/j.pan.2016.04.007. View

Mann D, Edwards R, Ho S, Lau W, Glazer G . Elevated tumour marker CA19-9: clinical interpretation and influence of obstructive jaundice. Eur J Surg Oncol. 2000; 26(5):474-9. DOI: 10.1053/ejso.1999.0925. View

10.

van Manen L, Groen J, Putter H, Vahrmeijer A, Swijnenburg R, Bonsing B . Elevated CEA and CA19-9 serum levels independently predict advanced pancreatic cancer at diagnosis. Biomarkers. 2020; 25(2):186-193. DOI: 10.1080/1354750X.2020.1725786. View

11.

Ryan D, Hong T, Bardeesy N . Pancreatic adenocarcinoma. N Engl J Med. 2014; 371(22):2140-1. DOI: 10.1056/NEJMc1412266. View

12.

Martin L, Wei L, Trolli E, Bekaii-Saab T . Elevated baseline CA19-9 levels correlate with adverse prognosis in patients with early- or advanced-stage pancreas cancer. Med Oncol. 2012; 29(5):3101-7. PMC: 3839283. DOI: 10.1007/s12032-012-0278-9. View

13.

van Veldhuisen E, Vogel J, Klompmaker S, Busch O, van Laarhoven H, van Lienden K . Added value of CA19-9 response in predicting resectability of locally advanced pancreatic cancer following induction chemotherapy. HPB (Oxford). 2018; 20(7):605-611. DOI: 10.1016/j.hpb.2018.01.001. View

14.

Brockhaus M, Magnani J, Blaszczyk M, Steplewski Z, KOPROWSKI H, Karlsson K . Monoclonal antibodies directed against the human Leb blood group antigen. J Biol Chem. 1981; 256(24):13223-5. View

15.

Daamen L, Groot V, Heerkens H, Intven M, van Santvoort H, Molenaar I . Systematic review on the role of serum tumor markers in the detection of recurrent pancreatic cancer. HPB (Oxford). 2018; 20(4):297-304. DOI: 10.1016/j.hpb.2017.11.009. View

16.

Asaoka T, Miyamoto A, Maeda S, Tsujie M, Hama N, Yamamoto K . Prognostic impact of preoperative NLR and CA19-9 in pancreatic cancer. Pancreatology. 2016; 16(3):434-40. DOI: 10.1016/j.pan.2015.10.006. View

17.

Isaji S, Mizuno S, Windsor J, Bassi C, Fernandez-Del Castillo C, Hackert T . International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017. Pancreatology. 2017; 18(1):2-11. DOI: 10.1016/j.pan.2017.11.011. View

18.

Imaoka H, Mizuno N, Hara K, Hijioka S, Tajika M, Tanaka T . Prognostic impact of carcinoembryonic antigen (CEA) on patients with metastatic pancreatic cancer: A retrospective cohort study. Pancreatology. 2016; 16(5):859-64. DOI: 10.1016/j.pan.2016.05.007. View

19.

Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y . FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011; 364(19):1817-25. DOI: 10.1056/NEJMoa1011923. View

20.

Pezzuto A, Spoto C, Vincenzi B, Tonini G . Short-term effectiveness of smoking-cessation treatment on respiratory function and CEA level. J Comp Eff Res. 2013; 2(3):335-43. DOI: 10.2217/cer.13.25. View